Sanofi, Glenmark In Pain Meds Deal | May 10, 2010 Issue - Vol. 88 Issue 19 | Chemical & Engineering News
Volume 88 Issue 19 | p. 21 | Concentrates
Issue Date: May 10, 2010

Sanofi, Glenmark In Pain Meds Deal

Department: Business
Keywords: collaboration, India, drug research, pain

In its first pharmaceutical research partnership in India, Sanofi-Aventis has licensed drug candidates for treating chronic pain from India’s Glenmark Pharmaceuticals. In return, Glenmark will receive an up-front fee and milestone payments that could total $325 million, as well as potential royalties. The agents are vanilloid receptor antagonists, which inhibit the TRPV3 receptor, an ion-channel protein that mediates and influences cell signaling. One candidate is in Phase I clinical development for treating diabetic neuropathic and osteoarthritic pain.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment